A new publication involving insulin degludec was indexed on October 19, 2026. The study, titled "Cardiovascular Outcomes of Insulin Degludec Versus Insulin Glargine in Trial-Eligible and Ineligible Populations: A DEVOTE-Inspired Target Trial Emulation Using the Swedish National Diabetes Register," appeared in Diabetes, Obesity & Metabolism. The paper uses a target trial emulation approach modeled on the DEVOTE trial design. It draws on data from the Swedish National Diabetes Register to examine both trial-eligible and trial-ineligible populations. The publication record does not include specific findings or outcome data in the information provided. Insulin degludec remains an approved compound. This entry reflects only the existence and bibliographic details of the publication as listed in the source record. Readers interested in background on insulin degludec can consult the compound overview for additional context.
Insulin Degludec vs Glargine Study Published in Diabetes, Obesity & Metabolism
See the full insulin degludec overview
Source: https://pubmed.ncbi.nlm.nih.gov/42897087/